viewImugene Ltd

Imugene in trading halt with capital raising news pending

The company’s securities are in a trading halt until Monday, December 2, or when an announcement is made to the market.

Imugene Ltd - Imugene in trading halt with capital raising pending
Imugene is developing drugs that seek to activate the immune system of cancer patients

Imugene Limited (ASX:IMU) has been granted a trading halt by the ASX with an announcement pending in relation to a proposed capital raising.

The trading halt will remain in place until the beginning of normal trading on Monday, December 2, 2019, or when an announcement is released to the market, whichever occurs earliest.

Imugene's securities last traded at 4.4 cents after reaching a new 12-month high of 6.3 cents on November 22.

Two separate phase-I clinical trials

Earlier this month the company recently revealed plans to conduct two separate phase-I clinical trials in 2020 to test two constructs of the CF 33 oncolytic virus (OV).

One version of the OV is “armed” with an immune checkpoint inhibitor inserted in the virus, which is known as CheckVacc.

The second is an unarmed construct known as Vaxinia.

Both constructs have completed clinical-grade GMP batches at the City of Hope Cenrtre for Biomedicne and Genetics (CBG).

Quick facts: Imugene Ltd

Price: 0.034 AUD

Market: ASX
Market Cap: $123.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read